Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more
Trump admin plan would pressure U.S.-listed Chinese companies
A Trump administration working group plan has recommended that Chinese companies listed on a U.S. stock exchange provide the Public Company Accounting Oversight Board with access to their auditing paperwork by Jan. 1, 2022, to maintain their listings. The plan, released Thursday by the President’s Working Group on Financial Markets, is similar to bipartisan legislation passed by the Senate in May (see “Proposed Legislation Could Deter Chinese Biotechs from U.S. Listings”).
Busy Thursday for Editas
Editas Medicine Inc. (NASDAQ:EDIT) found itself the subject of M&A rumors and revealed the unraveling of its Allergan deal on Thursday. The CRISPR gene editing company regained full control of its ocular programs, including EDIT-101, a gene therapy for Leber congenital amaurosis 10. The AbbVie Inc. (NYSE:ABBV) unit is eligible for clinical and regulatory milestones, plus royalties...